Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

BACKGROUND: Two randomized clinical trials have demonstrated a survival advantage with enzalutamide over placebo in both docetaxel (D)-pretreated and D-naïve metastatic castration-resistant prostate cancer (mCRPC) patients. Cross-resistance between androgen receptor-directed therapies and taxanes ha...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Nadal, Rosa, Zhang, Zhe, Rahman, Hibba, Schweizer, Michael T., Denmeade, Samuel R., Paller, Channing J., Carducci, Michael A., Eisenberger, Mario A., Antonarakis, Emmanuel S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176523/
https://ncbi.nlm.nih.gov/pubmed/25176007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22874
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky